Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Genmab A-SGMAB20.556.1325.47-0.2718.55%9.58%57.74$28.87$88.7810,028$26.425

Detail of Genmab A-S

 
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Employees
2526
Industry
Biotechnology
Sector
Healthcare
Market cap
$116B

Company details

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$18.97B
Cost of goods (CoG)
-$601.00M
Gross profit (GP)
$18.37B
Operating expense (OE)
-$12.36B
Research and development (R&D)
-$8.84B
General and administrative (G&A)
-$3.52B
Operating income (OI)
$6.00B
Other income expense (OIE)
-$382.00M
Pretax income (PI)
$7.47B
Tax (TAX)
-$1.97B
Net income (NI)
$5.50B
Genmab A-S
GMAB • XNGS • US
$26 .425
-10.93 (-29.26%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$1.29
Margin profit
29.13%
52 week low
$24.790001
52 week high
$36.529999
50-day simple moving average
$26.77
200-day simple moving average
$26.82
Percent held by insiders
0.01%
Percent held by institutions
7.85%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
GMAB -29.26%
eps change
GMAB +5.05%